Burson-Marsteller names Cohen new global chair

Burson-Marsteller has appointed Gail Cohen to global chair of the firm's healthcare practice. Cohen will report to Mark J. Penn, worldwide president and CEO. Cohen's new role began May 5.

“Gail has pioneered some of the industry's most successful pharmaceutical campaigns and has led numerous award-winning programs,” said Penn in a statement. “Her outstanding leadership skills and tremendous spirit will be essential to expanding our global healthcare practice, and vital to the quality of client service Burson-Marsteller is known for delivering across the globe.”

Cohen's responsibilities will include helping Burson-Marsteller's global healthcare practice strategically grow into new areas and drive success across regions, according to the statement. Prior to Burson-Marsteller, Cohen served on the Leadership Council for Chandler Chicco Companies (CCC). 

At CCC, she was responsible for driving new business initiatives, overseeing the agency's affiliate relationships with Asia-Pacific and the Americas, and assisting in creating unique branding platforms such as Buzz Matrix and Viractive. 

Additionally, Cohen led domestic and global campaigns at CCC for clinical development, scientific studies, patient advocacy, opinion leader relationships and life cycle management. Prior to joining CCC, she worked for boutique agencies focusing on consumer communications ranging from luxury goods to celebrity clients.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.